Evidence map›Paper›PMID 33124118›Full record

ArticleBJU international2021

The rising worldwide impact of benign prostatic hyperplasia.

Bryn M Launer, Kevin T McVary, William A Ricke, Granville L Lloyd

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 5 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 5 syntheses or guidelines pooled it, 196 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Investigative and clinical urology · 2021
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Investigative and clinical urology · 2023
    Trial
  11. Increased Expression of Desmin and Vimentin Impairs Mitochondrial Function and Reduces Contractility via G0S2 in Bladder Smooth Muscle.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. [Impact of thulium laser enucleation of the prostateBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Bryn M LaunerUniversity of Colorado Anschutz School of Medicine, Aurora, CO, USA.ORCID 0000-0002-3802-8709
Kevin T McVaryDepartment of Urology, Stritch School of Medicine, Center for Male Health, Loyola University Medical Center, Maywood, IL, USA.
William A RickeDepartment of Urology, George M. O'Brien Center of Research Excellence, University of Wisconsin-Madison, Madison, WI, USA.
Granville L LloydDepartment of Surgery/Urology, Rocky Mountain Regional VA Medical Center, University of Colorado Anschutz School of Medicine, Aurora, CO, USA.ORCID 0000-0003-0111-6809
Loyola University Medical Center · USRocky Mountain MS Center · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Wisconsin–Madison · US

Funding

Role of Beta-Catenin in Urinary DysfunctionU54DK104310 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2014 to 2023
$12.8M
Estrogen pathways in the development of prostatic fibrosis and lower urinary tract dysfunctionR01DK127081 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2021 to 2024
$2.0M
NIDDK NIH HHS R01 DK127081NIDDK NIH HHS U54 DK104310
6 · The paper itself

Abstract

objectivesTo describe the trend in the impact of lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH) on a global scale using the Global Burden of Disease (GBD) database. MATERIALS AND

methodsUsing the GBD database, worldwide data aggregated from registries and health systems from 1990 to 2017 were filtered for LUTS/BPH diagnoses. Calculation of years lived with disability (YLD) were compared with other urological diseases. YLD were calculated by a standardized method using assigned disability weights. The GBD-defined sociodemographic index (SDI) was used to assess impact of LUTS/BPH by global SDI quintile.

resultsGlobal Burden of Disease data over the 1990-2017 study period were summarized and global numbers and trends noted with other urological diseases for comparison. A total of 2 427 334 YLD were attributed to BPH in 2017 alone, almost three times more than those attributed to the next highest urological disease, prostate cancer (843 227 YLD). When stratified by SDI quintile, a much lower impact of BPH was found in the bottom three quintiles, despite this subset representing 66.9% of the 2017 world population.

conclusionsLower urinary tract symptoms attributed to benign prostatic hyperplasia exert a rapidly rising human burden far exceeding other urological diseases. As the population ages and men in a lower SDI enjoy increased life expectancy and decreased competing mortalities, a continually accelerating wave of LUTS/BPH can be forecast. These epidemiological trends have serious implications for the future allocation of resources and the global urological workforce.

Indexed as

Global Burden of DiseaseHumansLower Urinary Tract SymptomsMaleProstatic Hyperplasiabenign prostatic hyperplasiaglobal healthlower urinary tract symptomsprostatequality of life#UroBPH

Identifiers

PMID33124118
PMCPMC8170717
OpenAlexW3095578761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.